Novavax and Pfizer Strike Vaccine Licensing Deal Using Matrix-M

A landmark licensing arrangement between Pfizer and Novavax has the potential to change the landscape of vaccine development in the future.

Pfizer will have the right to use Novavax's Matrix-M adjuvant technology with non-exclusive rights on vaccines that combat up to two types of infectious diseases under the terms of the licensing agreement.

Consequently, the licensing agreement delivers a message to the pharmaceutical industry that Novavax's technology platform remains a valuable resource for manufacturers entering the market for the first time in a post-COVID environment.

Also Read: How a Culture of Thanks Fuels Retention in Hospitals

In exchange for the licensing terms, Novavax has received an immediately available payment of $30 million, and the possibility of receiving an additional $500 million in payments at specific milestone points in the development of new products through Pfizer. In addition, Novavax's royalty payments will consist of high mid-single-digit percentages on net sales of all products Pfizer manufactures and sells that include Matrix-M.

Pfizer will take on full responsibility for developing, producing, and Selling any vaccine products created with Matrix-M, while Novavax is responsible for supplying Matrix-M. The licensing agreement establishes that Novavax will begin collaborating with larger pharmaceutical companies to market its technology rather than solely selling its vaccine products.

Novavax’s CEO said the company is “excited about this agreement with Pfizer to access our Matrix-M technology in its future development plans,” showing confidence that the adjuvant can power new products across multiple disease areas.

Matrix-M stands out because it boosts immune response without aluminum, a feature that has drawn increased industry interest. With this deal, Novavax gains a strong validation of its science and a revenue path beyond its own COVID-19 vaccine sales. Analysts see the agreement as a key step in securing Novavax’s future growth through technology licensing.